The Clinical Utility of Indigo Carmine in Sentinel Lymph Nodes Biopsy of the Breast Cancer

Jae Bok Lee; Jeoung Won Bae; Gil Soo Son; Bum Hwan Koo

doi:10.4048/jbc.2006.9.1.18

Journal List > J Breast Cancer > v.9(1) > 1036782

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Lee, Bae, Son, and Koo: The Clinical Utility of Indigo Carmine in Sentinel Lymph Nodes Biopsy of the Breast Cancer

Original Article

Journal of Breast Cancer

Journal of Breast Cancer 2006; 9(1): 18-24.

Published online: 31 March 2006

DOI: https://doi.org/10.4048/jbc.2006.9.1.18

The Clinical Utility of Indigo Carmine in Sentinel Lymph Nodes Biopsy of the Breast Cancer

Jae Bok Lee, Jeoung Won Bae, Gil Soo Son, Bum Hwan Koo

Department of Surgery, Korea University College of Medicine, Seoul, Korea.

Correspondence: Jeoung Won Bae. Department of Surgery, Korea University College of Medicine, 126-1, 5th St. Anam Dong, Sungbuk Gu, Seoul, Korea. 136-705, Tel : 82-2-920-5305, Fax: 82-2-928-9231, kujwbae@unitel.co.kr

Received 18 November 2005 Accepted 14 February 2006

Abstract

Background

The selection of blue dye or technetium radioisotope depends on the surgeon's experience or the availability of the center in sentinel lymph node biopsy (SLNB). The purpose of this study is to evaluate the possibility of clinical usage of indigo carmine in SLNB in breast cancer.

Methods

From the July 2001 to the March 2004, 93 consecutive cases of Tis - T2 breast cancers without palpable axillary lymph nodes were enrolled to the SLNB. After usual preparation for the breast conserving surgery or mastectomy, the patients were intradermally injected with 5 ml of indigo carmine around the subareolar area. After 4 minutes has passed, usual axillary incision of breast conserving surgery was made, and the stained lymphatics were followed to the firstly encountered lymph nodes. The dissected nodes were sent to the department of pathology for frozen and permanent sections. After SLNB, axillary lymph node dissections (ALND) were completed regardless of the result of the frozen section.

Results

The identification rate of SLNB using Indigo carmine was 97.8% (91/93). The axillary node metastases on complete ALND were 21 cases. 18 cases were detected with SLNB, and 3 cases were falsely reported as negative on SLNB. 11 cases had metastases in the sentinel nodes only (52.4%). Among the 3 false negative cases, one case had axillary metastasis solely in a node in level III (infraclavicular node). The sensitivity of the test was 85.7% (18/21), and the specificity was 100% (70/70). False negative rate was 9.5% (2/21), and negative predictive value was 95.9% (70/73).

Conclusion

Sentinel node biopsy using indigo carmine showed similar identification rate and false negative rate with other blue dye only methods including isosulfan blue. Because indigo carmine is more available and safe than isosulfan blue, it could be an alternative to isosulfan blue.

Keywords: Breast cancer, Sentinel lymph node biopsy, Indigo Carmine

References

1. Hansen NM, Grube BJ, Giuliano AE. The time has come to change the algorithm for the surgical management of early breast cancer. Arch Surg. 2002. 137:1131–1135.

2. Leong SP, Morita ET, Treseler PA, Wong JH. Multidisciplinary approach to selective sentinel lymph node mapping in breast cancer. Breast Cancer. 2000. 7:105–113.

3. Staradub VL. Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Technique in surgery, sentinel node biopsy and axillary dissection. Diseases of the breast. 2004. 3rd ed. Philadelphia: Lippincott Williams & Wilkins.

4. Raut CP, Daley MD, Hunt KK, Akins J, Ross MI, Singletary SE, et al. Anaphylactoid reactions to isosulfan blue dye during breast cancer lymphatic mapping in patients given preoperative prophylaxis. J Clin Oncol. 2004. 22:567–568.

5. Sprung J, Tully MJ, Ziser A. Anaphylactic reactions to isosulfan blue dye during sentinel node lymphadenectomy for breast cancer. Anesth Analg. 2003. 96:1051–1053.

6. Quiney NF, Kissin MW, Tytler I. Anaphylactic reaction to isosulphan blue. Br J Anaesth. 2003. 90:105–106.

7. Stefanutto TB, Shapiro WA, Wright PM. Anaphylactic reaction to isosulphan blue. Br J Anaesth. 2002. 89:527–528.

8. Sadiq TS, Burns WW 3rd, Taber DJ, Damitz L, Ollila DW. Blue urticaria: a previously unreported adverse event associated with isosulfan blue. Arch Surg. 2001. 136:1433–1435.

9. Albo D, Wayne JD, Hunt KK, Rahlfs TF, Singletary SE, Ames FC, et al. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg. 2001. 182:393–398.

10. Kuerer HM, Hunt KK, Singletary SE, Ames FC. Unusual aspects of breast cancer: case 3. Blue hives during lymphatic mapping for breast cancer. J Clin Oncol. 2001. 19:2573–2574.

11. Lyew MA, Gamblin TC, Ayoub M. Systemic anaphylaxis associated with intramammary isosulfan blue injection used for sentinel node detection under general anesthesia. Anesthesiology. 2000. 93:1145–1146.

12. Longnecker SM, Guzzardo MM, Van Voris LP. Life-threatening anaphylaxis following subcutaneous administration of isosulfan blue 1%. Clin Pharm. 1985. 4:219–221.

13. Kern KA. Sentinel lymph node mapping in breast cancer using subareolar injection of blue dye. J Am Coll Surg. 1999. 189:539–545.

14. Aihara T, Takatsuka Y. Dye-guided sentinel node biopsy revisited; validation and observational study from a single institute. Breast Cancer. 2003. 10:254–259.

15. Lee EK, Park YL, Pae WK. Endoscopic sentinel node biopsy. J Korea Breast Cancer Soc. 2003. 6:174–179.

16. Tsopelas C, Sutton R. Why certain dyes are useful for localizing the sentinel lymph node. J Nucl Med. 2002. 43:1377–1382.

17. Noguchi M, Motomura K, Imoto S, Miyauchi M, Sato K, Iwata H, et al. A multicenter validation study of sentinel lymph node biopsy by the Japanese Breast Cancer Society. Breast Cancer Res Treat. 2000. 63:31–40.

18. Yang JH, Lee SD, Park HL, Nam SJ, Ko YH, Ree HJ, et al. Clinical application of sentinel node biopsy in T1 or less breast cancers: is it effective or feasible? J Korea Breast Cancer Soc. 1992. 2:146–151.

19. Choi JW, Lee HD, Park BW, Jung WH, Oh KK, Ryu YH. Experiences with sentinel lymphadenectomy in 157 cases of breast carcinoma. J Korea Breast Cancer Soc. 2002. 5:38–45.

20. Park JM, Jin SH, Kim MW, Yim HE, Park CH, Chung KI, et al. Sentinel lymph node biopsy using technetium- 99m antimony sulfide colloid and isosulfan blue dye in breast cancer patients. J Korea Breast Cancer Soc. 2002. 5:168–174.

21. Kim SW, Park IA, Chung JK, Yeo JS, Moon WK, Cha JH, et al. Prospective study of 162 sentinel lymph node biopsies in breast cancer: usefulness of ultrasonography in patients selection. J Korea Breast Cancer Soc. 2003. 6:103–108.

22. Kang SH, Lee ES, Kang HS, Ro JS, Lee S, Kang KW. Neoadjuvant chemotherapy decreases the identification rate of sentinel lymph node biopsy. J Korea Breast Cancer Soc. 2003. 6:95–102.

23. Schwartz GF. Clinical practice guidelines for the use of axillary sentinel lymph node biopsy in carcinoma of the breast: current update. Breast J. 2004. 10:85–88.

24. O'Hea BJ, Hill AD, El-Shirbiny AM, Yeh SD, Rosen PP, Coit DG, et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg. 1998. 186:423–427.

25. Imoto S, Hasebe T. Initial experience with sentinel node biopsy in breast cancer at the National Cancer Center Hospital East. Jpn J Clin Oncol. 1999. 29:11–15.

26. Chagpar A, Martin RC 3rd, Chao C, Wong SL, Edwards MJ, Tuttle T, et al. Validation of subareolar and periareolar injection techniques for breast sentinel lymph node biopsy. Arch Surg. 2004. 139:614–618. discussion 618-20.

TOOLS

Similar articles